Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/7/2025

Lymphocytosis Evaluation and Management

Initial Diagnostic Approach

  • The American College of Physicians recommends that patients with lymphocytosis undergo a systematic evaluation to distinguish between reactive causes and lymphoproliferative disorders, with a focus on medication exposure, infectious symptoms, and autoimmune history 1, 2
  • A thorough physical examination should assess for lymphadenopathy, splenomegaly, hepatomegaly, skin examination, and nutritional status, as recommended by the American College of Physicians 1, 2

Laboratory Workup

  • The CDC recommends that flow cytometry data should achieve ≥85% lymphocyte purity within the lymphocyte gate, with optimal purity ≥90%, for accurate immunophenotyping 4, 5
  • A complete blood count with manual differential and peripheral blood smear are essential for accurate lymphocyte subset assessment and evaluation of other cell lines, as recommended by the American Society of Clinical Oncology 1, 2, 3

Differential Diagnosis

  • Viral infections such as EBV, CMV, HIV, and hepatitis viruses can cause transient lymphocytosis with atypical lymphocytes, as noted by the Infectious Diseases Society of America 1, 2
  • Bacterial infections like pertussis and tuberculosis can also cause lymphocytosis, as reported by the American Thoracic Society 1
  • Autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis can cause lymphocytosis, as noted by the American College of Rheumatology 1, 2

Clinical Decision Algorithm

  • The American College of Physicians recommends obtaining a CBC with manual differential and peripheral smear immediately for patients with absolute lymphocyte count 7.82 × 10⁹/L 1, 2, 3
  • If lymphocytosis persists >4 weeks or patient >50 years with relative lymphocytosis ≥50%, flow cytometry is mandatory, as recommended by the American Society of Clinical Oncology 1, 2